13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q3 2024 · Filed November 14, 2024 · Accession 0000950123-24-011486
Total Value
$160.0M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $56.2M | 35.09% |
| 2 | Nuvation Bio | NUVB | 13,072,340 | $29.9M | 18.71% |
| 3 | Replimune Group | REPL | 2,461,319 | $27.0M | 16.86% |
| 4 | Lexeo Therapeutics | LXEO | 2,355,904 | $21.3M | 13.31% |
| 5 | enGene Holdings Inc. | ENGNW | 1,076,357 | $7.1M | 4.44% |
| 6 | Alumis Inc | ALMS | 653,223 | $7.0M | 4.36% |
| 7 | Ikena Oncology | 45175G108 | 2,249,123 | $3.9M | 2.43% |
| 8 | Sana Biotechnology, Inc. | SANA | 843,750 | $3.5M | 2.19% |
| 9 | Immunic Inc | IMUX | 1,788,160 | $3.0M | 1.84% |
| 10 | enGene Holdings Inc. | ENGNW | 321,502 | $675,154 | 0.42% |
| 11 | Syros Pharmaceuticals | 87184Q206 | 251,270 | $540,231 | 0.34% |